EMPIRE CONSULTING GROUP

Lobbying for AMGEN INC. · Healthcare/Biotechnology

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 18, 2026

Lobbying activity 1

Health Issues

Issues related to health access. PBM reform. Most-Favored-Nation pricing for pharmaceuticals. 340B.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.